ALK and non-small cell lung carcinoma: The SAFIR02_Lung (NCT02117167) is a phase II study, enrolling advanced NSCLC patients, wild type for EGFR activating mutations, or EML4-ALK rearrangement, who have stable disease or partial response following four cycles of an induction platinum-based chemotherapy.